Oral metronomic chemotherapy is a cost effective alternative to pazopanib in advanced soft tissue sarcoma.
Aparna SharmaBabita KatariaBivas BiswasSameer BakhshiDeepam PushpamPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2021)
Our study demonstrates that OMT have a similar progression free survival (PFS) and overall survival (OS) in metastatic STS. This study raises the possibility that OMT might be an equally efficacious and less toxic alternative to pazopanib, without compromising survival outcome especially in LMIC.